Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Recombinant DNA technology in the treatment of diabetes: Insulin analogs
Autore:
Vajo, Z; Fawcett, J; Duckworth, WC;
Indirizzi:
Vet Adm Med Ctr, Endocrinol Sect, Phoenix, AZ 85012 USA Vet Adm Med Ctr Phoenix AZ USA 85012 docrinol Sect, Phoenix, AZ 85012 USA
Titolo Testata:
ENDOCRINE REVIEWS
fascicolo: 5, volume: 22, anno: 2001,
pagine: 706 - 717
SICI:
0163-769X(200110)22:5<706:RDTITT>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
LONG-ACTING INSULIN; POSTPRANDIAL GLYCEMIC CONTROL; BIOSYNTHETIC HUMAN PROINSULIN; DOUBLE-BLIND CROSSOVER; SOLUBLE HUMAN INSULIN; TIME-ACTION PROFILE; NPH INSULIN; RECEPTOR-BINDING; BLOOD-GLUCOSE; SUBCUTANEOUS INJECTION;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
130
Recensione:
Indirizzi per estratti:
Indirizzo: Duckworth, WC Vet Adm Med Ctr, Endocrinol Sect, 650 E Indian Sch Rd,11E, Phoenix, AZ 85012 USA Vet Adm Med Ctr 650 E Indian Sch Rd,11E Phoenix AZ USA85012
Citazione:
Z. Vajo et al., "Recombinant DNA technology in the treatment of diabetes: Insulin analogs", ENDOCR REV, 22(5), 2001, pp. 706-717

Abstract

After more than half a century of treating diabetics with animal insulins,recombinant DNA technologies and advanced protein chemistry made human insulin preparations available in the early 1980s. As the next step, over the last decade, insulin analogs were constructed by changing the structure of the native protein with the goal of improving the therapeutic properties ofit, because the pharmacokinetic characteristics of rapid-, intermediate-, and long-acting preparations of human insulin make it almost impossible to achieve sustained normoglycemia. The first clinically available insulin analog, lispro, confirmed the hopes by showing that improved glycemic control can be achieved without an increase in hypoglycemic events. Two new insulinanalogs, insulin glargine and insulin aspart, have recently been approved for clinical use in the United States, and several other analogs are being intensively tested. Thus, it appears that a rapid acceleration of basic andclinical research in this arena will be seen, which will have direct significance to both patients and their physicians. The introduction of new short-acting analogs and the development of the first truly long-acting analogsand the development of analogs with increased stability, less variability,and perhaps selective action, win help to develop more individualized treatment strategies targeted to specific patient characteristics and to achieve further improvements in glycemic control. Data on the currently availableand tested analogs, as well as data on those currently being developed, are reviewed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 11:19:21